Xeroderma pigmentosum skin: an immune privilege site for tumor development
Corresponding Author
Kalthoum Abid
Immuno-Histology Laboratory, Medicine University of Tunis, Tunisia
Kalthoum Abid, Immuno-Histology Laboratory, Medicine University of Tunis, 15, Rue Djebel Lakhdar, 1007 Bab Saadoun, Tunis, TunisiaTel: +216 98 64 88 50Fax: +216 71 887 030e-mail: [email protected]Search for more papers by this authorFaouzi El Mezni
Department of Anatomo-Pathology, A. Mami Hospital, Lariana, Tunisia
Search for more papers by this authorMohamed Ridha Kamoun
Dermatology Department, Charles Nicolle Hospital, 1060 Tunis, Tunisia
Search for more papers by this authorBecima Fazaa
Dermatology Department, Charles Nicolle Hospital, 1060 Tunis, Tunisia
Search for more papers by this authorRachida Zermani
Department of Anatomo-Pathology, Charles Nicolle Hospital, 1060 Tunis, Tunisia
Search for more papers by this authorChokri Hadouchi
Department of Anatomo-Pathology, A. Mami Hospital, Lariana, Tunisia
Search for more papers by this authorKamel Hamzaoui
Immuno-Histology Laboratory, Medicine University of Tunis, Tunisia
Search for more papers by this authorCorresponding Author
Kalthoum Abid
Immuno-Histology Laboratory, Medicine University of Tunis, Tunisia
Kalthoum Abid, Immuno-Histology Laboratory, Medicine University of Tunis, 15, Rue Djebel Lakhdar, 1007 Bab Saadoun, Tunis, TunisiaTel: +216 98 64 88 50Fax: +216 71 887 030e-mail: [email protected]Search for more papers by this authorFaouzi El Mezni
Department of Anatomo-Pathology, A. Mami Hospital, Lariana, Tunisia
Search for more papers by this authorMohamed Ridha Kamoun
Dermatology Department, Charles Nicolle Hospital, 1060 Tunis, Tunisia
Search for more papers by this authorBecima Fazaa
Dermatology Department, Charles Nicolle Hospital, 1060 Tunis, Tunisia
Search for more papers by this authorRachida Zermani
Department of Anatomo-Pathology, Charles Nicolle Hospital, 1060 Tunis, Tunisia
Search for more papers by this authorChokri Hadouchi
Department of Anatomo-Pathology, A. Mami Hospital, Lariana, Tunisia
Search for more papers by this authorKamel Hamzaoui
Immuno-Histology Laboratory, Medicine University of Tunis, Tunisia
Search for more papers by this authorAbstract
A unique feature of the skin immune system is its proximity to cells continuously exposed to sun rays, as it is located in the interface between the body and the environment.
In this study, we aimed to determine the impact of DNA damaged keratinocytes on the expression of apoptotic-related molecules, in T-cells of the inflammatory component of the tumor environment. Immunohistochemistry was performed on tissue sections derived from skin biopsies of basal cell carcinomas (BCCs) of xeroderma pigmentosum (XP) patients, non-XP patients and nevoid basal cell carcinoma syndrome (NBCCS) patients, using antibodies against B-cell lymphoma/leukemia-2 (Bcl-2), Bcl-2 associated X protein (Bax), CD95, CD3, CD8 and CD56.
Our results showed significantly lower levels of expression of the antiapoptotic Bcl-2 molecule, in XP, in comparison with non-XP and NBCCS T-lymphocytes, leading to the highest Bax/Bcl-2 ratio for XP T-cells. For the CD95 receptor expression levels, there were significant differences among T-cells of the three patient subgroups as well.
The higher propensity of XP T-cells to undergo apoptosis may have evolved in individual XP patients, apparently during the course of their disease, to maintain a special skin as an immune privilege site for tumors' development.
Abid K, El Mezni F, Kamoun MR, Fazaa B, Zermani R, Hadouchi C, Hamzaoui K. Xeroderma pigmentosum skin: an immune privilege site for tumor development.
References
- 1 Cleaver JE, Layher S. If the shoe fits: clues on structural recognition of DNA damage. Cell 1995; 80: 825.
- 2 Cleaver JE. Xeroderma pigmentosum: the first of the cellular caretakers. Trends Biol Sci 2001; 26: 398.
- 3 Suzuki H, Kalair W, Shivji GM, et al. Impaired ultraviolet-B-induced cytokine induction in xeroderma pigmentosum fibroblasts. J Invest Dermatol 2001; 117: 1151.
- 4 Gorlin RJ. Nevoid basal cell carcinoma syndrome. Medicine 1987; 66: 98.
- 5 Fan Z, Li J, Du J, et al. A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet 2008; 45: 303.
- 6 Kupper TS. Mechanisms of cutaneous inflammation. Interactions between epidermal cytokines, adhesion molecules, and leukocytes. Arch Dermatol 1989; 125: 1406.
- 7 Galkowska H, Wojewodzka U, Olszewski L. Cytokine and adherence molecules involved in spontaneous dendritic cell clustering in skin afferent lymph. Scand Immunol 1995; 42: 324.
- 8 Bruggers CS, Patel DD, Scerace RM, Whichard LP, Haynes BF, Singer KH. AD2, a human molecule involved in the interaction of T cells with epidermal keratinocytes and thymic epithelial cells. J Immunol 1995; 154: 2012.
- 9 Veis DJ, Sorenson CM, Shutter JR, Crosmeyer SJ. Bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair. Cell 1993; 75: 229.
- 10 Puthalakah H, Huang DC, O’Reilly LA, King SM, Strasser A. The proapoptotic activity of Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 1999; 3: 287.
- 11 Dlugosz PJ, Billen LP, Annis MG, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO J 2006; 25: 2287.
- 12 Yin XM, Oltvai ZN, Krosmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321.
- 13 Oehm A, Behrmann I, Falk W, et al. Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the TNF/NGF receptor family. Sequence identity with Fas antigen. J Biol Chem 1992; 267: 10709.
- 14 Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas-L in activated lymphocytes. EMBO J 1995; 14: 1129.
- 15 Henkart PA. ICE family proteases: mediators of all apoptotic cell death ? Immunity 1996; 4: 195.
- 16 Hanada M, Aime-Semye C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995; 270: 11962.
- 17 Srinivas G, Kusumakumary P, Nair MK, Panicker KR, Pillai MR. Mutant p53 protein, Bcl-2/Bax ratio and apoptosis in paediatric acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2000; 126: 62.
- 18 Salakou S, Kardamakis D, Tsamandas AC, et al. Increased Bax/Bcl-2 ratio upregulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo 2007; 21: 123.
- 19 Danial NK, Krosmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205.
- 20 Coussens LM Werb Z. Inflammation and cancer. Nature 2002; 420: 860.
- 21 Parijs LV, Peterson DA, Abbas AK. The Fas/Fas-L pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998; 8: 265.
- 22 Singer GG, Carrera AC, Marshak-Rothstein A, Martinez-A C, Abbas AK. Apoptosis, Fas and systemic immunity: the MRL-Ipr/Ipr model. Curr Op Immunol 1994; 6: 913.
- 23 Dunkern TR, Fritz G, Kaina B. UV light-induced DNA damage triggers apoptosis in nucleotide excision repair-deficient cells via Bcl-2 decline and caspase-3/-8 activation. Oncogene 2001; 20: 6026.
- 24 Nagata S, Goldstein P The Fas death factor. Science 1995; 267: 1449.
- 25 Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human lymphocytes. J Exp Med 1993; 178: 2231.
- 26
Sakata K,
Sakata A,
Vela-Roch N, et al.
Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes.
Eur J Immunol
1998; 28: 2648.
10.1002/(SICI)1521-4141(199809)28:09<2648::AID-IMMU2648>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 27 Peter ME, Budd RC, Desbarats J, et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129: 447.
- 28 Restifo NP. Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nature Med 2000; 6: 493.
- 29 Abid K, Fazaa B, Hadouchi Ch, El Mezni F, Kamoun MR, Hamzaoui K. Differential expression of Bcl-2, Bax and CD95 in DNA repair-proficient and DNA repair-deficient basal cell carcinoma patients. Int J Dermatol 2006; 45: 1482.
- 30 Rivoltini LM, Carrabba M, Huber V, et al. Immunity to cancer : attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002; 188: 97.
- 31 Hanahan D, Weinberg RA. The hallmarks of cancer Cell 2000; 100: 57.
- 32 Vineis P. Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis 2003; 24: 1.
- 33 Gennery AR, Cant AJ, Jeggo PA. Immunodeficiency associated with DNA repair defects. Clin Exp Immunol 2000; 121: 1.
- 34 Garssen J, Van Steeg HV, De Gruijl F et al Transcription-coupled and global genome repair differentially influence UV-B-induced acute skin effects and systemic immunosuppression. The J Immunol 2000; 164: 6199.
- 35 Moodycliffe AM, Nqhiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; Dec 1; 6: 521.
- 36 Seo N, Hayakawa S, Tokura Y Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 2002; 12: 291.
Citing Literature
